G protein-coupled receptors, or GPCRs, are proteins embedded in cell membranes that detect signals outside the cell and trigger responses inside it. They are the largest family of receptor proteins in the human body, and roughly 35% of all approved drugs target them. Understanding how they work means following a chain of events: a signal molecule lands on the receptor’s outer surface, the receptor changes shape, and that shape change activates a series of molecular switches inside the cell.
The Basic Structure
Every GPCR shares the same core architecture: a single protein chain that threads back and forth through the cell membrane seven times, forming seven column-like segments arranged in a roughly cylindrical bundle. Viewed from outside the cell, these seven columns are arranged counter-clockwise in numerical order, with the first column sitting next to the seventh to complete the circle. This “bundle of rods” design is so distinctive that GPCRs are sometimes called seven-transmembrane receptors.
The loops connecting these columns on the outside of the cell, along with the protein’s starting tail, form the extracellular domain. This is where signal molecules dock. The loops on the inside of the cell, along with the protein’s ending tail, form the intracellular domain. This is the surface that communicates with the cell’s internal machinery. Three loops face outward and three face inward, giving the receptor plenty of surface area on both sides of the membrane to interact with other molecules.
What Happens When a Signal Arrives
When a signal molecule (called a ligand) binds to the receptor’s outer surface, it doesn’t just flip a switch. It physically reshapes the receptor. The most dramatic movement occurs in the sixth transmembrane column, which swings outward on the intracellular side, rotating away from the bundle’s center. The third column also shifts outward, though to a lesser degree. At the same time, the outer ends of the third and seventh columns move closer together, while the inner ends of the first and seventh columns spread apart.
These movements may sound subtle, but they transform the receptor’s inner surface from a shape that ignores the cell’s internal signaling proteins to one that grabs onto them. The outward swing of the sixth column is especially critical because it opens up a cavity on the intracellular side where a G protein can dock.
The G Protein Cycle
G proteins are the receptor’s primary messengers inside the cell. Each G protein is made of three parts: an alpha subunit, a beta subunit, and a gamma subunit. In its resting state, the alpha subunit holds onto a molecule called GDP, which keeps the whole complex inactive and assembled as a unit.
When the activated receptor grabs hold of this resting G protein, it forces a conformational change in the alpha subunit. Part of the alpha subunit rotates and shifts away from where GDP sits, weakening the grip on GDP and allowing it to fall out. Because GTP (a similar but higher-energy molecule) is abundant inside the cell, GTP quickly fills the empty slot. This swap from GDP to GTP is the key activation event.
Once GTP is in place, the alpha subunit separates from the beta-gamma pair. Both pieces are now free to travel along the inner surface of the membrane and activate different downstream targets. The signal has been handed off from outside the cell to inside it.
Three Major Signaling Pathways
Not all G proteins do the same thing. The alpha subunit comes in several varieties, and each type triggers a different chain of events inside the cell.
- Gs (stimulatory): The alpha subunit activates an enzyme that converts ATP into a small signaling molecule called cAMP. Rising cAMP levels then activate protein kinase A, which goes on to switch on genes and alter cell behavior. This pathway plays roles in heart rate, hormone release, and energy metabolism.
- Gi (inhibitory): This alpha subunit does the opposite, blocking the same enzyme that Gs activates. The result is lower cAMP levels inside the cell. Gi signaling acts as a brake on many of the processes Gs accelerates.
- Gq: Instead of affecting cAMP, this alpha subunit activates an enzyme that breaks a specific membrane fat into two signaling molecules: IP3 and DAG. IP3 triggers calcium release from internal stores, while DAG activates another enzyme called protein kinase C. This pathway is central to muscle contraction, immune cell activation, and many other functions.
A single GPCR can sometimes couple to more than one type of G protein, meaning one receptor can activate multiple pathways depending on the context.
How the Signal Gets Shut Off
Cells need to stop responding once a signal has been received, and GPCRs have an efficient two-step shutdown process. First, specialized enzymes called GRKs add phosphate groups to the receptor’s intracellular tail while it’s still in its active shape. This phosphorylation creates a docking site for proteins called beta-arrestins.
Beta-arrestins do double duty. They physically block the G protein from re-attaching to the receptor, cutting off that communication channel. They also recruit enzymes that break down the second messengers (like cAMP and DAG) that were just generated, mopping up the downstream signal as well. For example, beta-arrestins bring in phosphodiesterases that convert cAMP back into inactive AMP, and diacylglycerol kinases that neutralize DAG.
Meanwhile, the alpha subunit of the G protein has its own off switch. It slowly converts its bound GTP back into GDP, which deactivates it and causes it to reassemble with the beta-gamma pair. The whole system resets, ready to respond to the next signal.
GPCR Families
There are six recognized families of GPCRs, though three dominate in human biology. Family A, the rhodopsin family, is by far the largest and includes receptors for light, smell, hormones like adrenaline, and neurotransmitters like serotonin and dopamine. Family B, the secretin-receptor family, responds to peptide hormones and is important in regulating blood sugar and bone metabolism. Family C, the metabotropic glutamate receptor family, responds to the brain’s primary excitatory neurotransmitter and to taste molecules.
Despite sharing the seven-transmembrane design, these families have very little sequence similarity to one another. The seven-column architecture likely evolved independently multiple times, which makes it a striking example of different evolutionary paths converging on the same structural solution.
Why GPCRs Matter for Medicine
An estimated 700 approved drugs target GPCRs, making them the single largest family of drug targets. That accounts for roughly 35% of all approved medications, more than any other protein family. Drugs for allergies, high blood pressure, depression, pain, asthma, and acid reflux all work by either activating or blocking specific GPCRs.
Mutations in GPCRs also cause disease directly. Over 600 inactivating mutations and nearly 100 activating mutations have been linked to more than 30 human diseases, including retinitis pigmentosa (a form of progressive blindness), certain thyroid disorders, a form of diabetes insipidus that affects kidney water retention, and several fertility disorders. Some activating mutations can even drive cancer by keeping growth-promoting signals permanently switched on.
Biased Signaling and Smarter Drugs
Traditional drugs that target GPCRs activate or block the receptor at its main binding site, which means they tend to trigger every downstream pathway the receptor is connected to. In many cases, one of those pathways produces the desired therapeutic effect while another causes side effects. Both responses come from the same receptor, which is why certain medications work well but carry significant drawbacks.
A newer approach involves designing molecules that push the receptor toward one signaling branch while leaving others quiet. This concept, called biased signaling, takes advantage of the fact that GPCRs don’t just flip between “on” and “off.” They can adopt different active shapes, and each shape may preferentially engage G proteins or beta-arrestins. A biased drug could, in principle, activate only the beneficial pathway. Even partial bias toward the desired pathway has therapeutic potential.
Another strategy uses allosteric modulators: molecules that bind to a site on the receptor different from where the natural signal molecule binds. Positive allosteric modulators boost the receptor’s response to its natural signal, while negative allosteric modulators dampen it. Because allosteric sites vary more between closely related receptor subtypes than the main binding sites do, these modulators can be more selective, reducing off-target effects. They also preserve the natural timing and pattern of signaling rather than overriding it, which can produce a more physiologically balanced response.